Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan

{ 'indexed': {'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T02:41:53Z', 'timestamp': 1647830513388}, 'reference-count': 39, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T00:00:00Z', 'timestamp': 1647820800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T00:00:00Z', 'timestamp': 1647820800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [ { 'DOI': '10.13039/501100003478', 'name': 'Ministry of Health, Labour and Welfare', 'doi-asserted-by': 'publisher', 'award': ['19HA1003']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'short-container-title': ['Infect Dis Ther'], 'DOI': '10.1007/s40121-022-00617-9', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T02:02:48Z', 'timestamp': 1647828168000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large ' 'Observational Study Using the COVID-19 Registry Japan'], 'prefix': '10.1007', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-5732-846X', 'authenticated-orcid': False, 'given': 'Shinya', 'family': 'Tsuzuki', 'sequence': 'first', 'affiliation': []}, {'given': 'Kayoko', 'family': 'Hayakawa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yohei', 'family': 'Doi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tomohiro', 'family': 'Shinozaki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yukari', 'family': 'Uemura', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nobuaki', 'family': 'Matsunaga', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mari', 'family': 'Terada', 'sequence': 'additional', 'affiliation': []}, {'given': 'Setsuko', 'family': 'Suzuki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yusuke', 'family': 'Asai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gen', 'family': 'Yamada', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sho', 'family': 'Saito', 'sequence': 'additional', 'affiliation': []}, {'given': 'Taro', 'family': 'Shibata', 'sequence': 'additional', 'affiliation': []}, {'given': 'Masashi', 'family': 'Kondo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kazuo', 'family': 'Izumi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Masayuki', 'family': 'Hojo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tetsuya', 'family': 'Mizoue', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kazuhisa', 'family': 'Yokota', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fukumi', 'family': 'Nakamura-Uchiyama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fumitake', 'family': 'Saito', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wataru', 'family': 'Sugiura', 'sequence': 'additional', 'affiliation': []}, {'given': 'Norio', 'family': 'Ohmagari', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 3, 21]]}, 'reference': [ { 'key': '617_CR1', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'volume': '93', 'author': 'Y Furuta', 'year': '2017', 'unstructured': 'Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum ' 'inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. ' '2017;93:449–63.', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': '617_CR2', 'unstructured': 'Information of Avigan Tablet in relation to Covid-19 | FUJIFILM Toyama ' 'Chemical Co.. https://www.fujifilm.com/fftc/en/avigan. Accessed 8 Nov ' '2021.'}, { 'key': '617_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1288', 'DOI': '10.1093/cid/ciw571', 'volume': '63', 'author': 'C-Q Bai', 'year': '2016', 'unstructured': 'Bai C-Q, Mu J-S, Kargbo D, et al. Clinical and virological ' 'characteristics of Ebola virus disease patients treated with favipiravir ' '(T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016;63:1288–94.', 'journal-title': 'Clin Infect Dis'}, { 'key': '617_CR4', 'doi-asserted-by': 'publisher', 'first-page': 'e1001967', 'DOI': '10.1371/journal.pmed.1001967', 'volume': '13', 'author': 'D Sissoko', 'year': '2016', 'unstructured': 'Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with ' 'favipiravir for Ebola virus disease (the JIKI Trial): a historically ' 'controlled, single-arm proof-of-concept trial in guinea. PLoS Med. ' '2016;13:e1001967.', 'journal-title': 'PLoS Med'}, { 'key': '617_CR5', 'doi-asserted-by': 'publisher', 'first-page': 'e01897-20', 'DOI': '10.1128/AAC.01897-20', 'volume': '64', 'author': 'Y Doi', 'year': '2020', 'unstructured': 'Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label ' 'trial of early versus late favipiravir therapy in hospitalized patients ' 'with COVID-19. Antimicrob Agents Chemother. 2020;64:e01897-20.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '617_CR6', 'doi-asserted-by': 'publisher', 'first-page': '96', 'DOI': '10.35772/ghm.2020.01034', 'volume': '2', 'author': 'K Ito', 'year': '2020', 'unstructured': 'Ito K, Ohmagari N, Mikami A, Sugiura W. Major ongoing clinical trials ' 'for COVID-19 treatment and studies currently being conducted or ' 'scheduled in Japan. Glob Health Med. 2020;2:96–101.', 'journal-title': 'Glob Health Med'}, { 'key': '617_CR7', 'doi-asserted-by': 'publisher', 'first-page': '531', 'DOI': '10.1093/cid/ciaa1176', 'volume': '73', 'author': 'AA Ivashchenko', 'year': '2021', 'unstructured': 'Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment ' 'of patients with moderate coronavirus disease 2019 (COVID-19): interim ' 'results of a phase\xa0II/III multicenter randomized clinical trial. Clin ' 'Infect Dis. 2021;73:531–4.', 'journal-title': 'Clin Infect Dis'}, { 'key': '617_CR8', 'doi-asserted-by': 'publisher', 'first-page': '2489', 'DOI': '10.1007/s40121-021-00517-4', 'volume': '10', 'author': 'M Shinkai', 'year': '2021', 'unstructured': 'Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and safety of ' 'favipiravir in moderate COVID-19 pneumonia patients without oxygen ' 'therapy: a randomized, phase\xa0III clinical trial. Infect Dis Ther. ' '2021;10:2489–509.', 'journal-title': 'Infect Dis Ther'}, { 'key': '617_CR9', 'doi-asserted-by': 'publisher', 'first-page': '62', 'DOI': '10.1016/j.ijid.2020.11.142', 'volume': '103', 'author': 'ZF Udwadia', 'year': '2021', 'unstructured': 'Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of ' 'favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in ' 'mild-to-moderate COVID-19: a randomized, comparative, open-label, ' 'multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.', 'journal-title': 'Int J Infect Dis'}, { 'key': '617_CR10', 'doi-asserted-by': 'publisher', 'first-page': '2291', 'DOI': '10.1007/s40121-021-00496-6', 'volume': '10', 'author': 'M Bosaeed', 'year': '2021', 'unstructured': 'Bosaeed M, Mahmoud E, Alharbi A, et al. Favipiravir and ' 'hydroxychloroquine combination therapy in patients with moderate to ' 'severe COVID-19 (FACCT Trial): an open-label, multicenter, randomized, ' 'controlled trial. Infect Dis Ther. 2021;10:2291–307.', 'journal-title': 'Infect Dis Ther'}, { 'key': '617_CR11', 'doi-asserted-by': 'publisher', 'first-page': '767', 'DOI': '10.1016/j.jmii.2021.05.011', 'volume': '54', 'author': 'C-C Lai', 'year': '2021', 'unstructured': 'Lai C-C, Chao C-M, Hsueh P-R. Clinical efficacy of antiviral agents ' 'against coronavirus disease 2019: a systematic review of randomized ' 'controlled trials. J Microbiol Immunol Infect. 2021;54:767–75.', 'journal-title': 'J Microbiol Immunol Infect'}, { 'key': '617_CR12', 'doi-asserted-by': 'publisher', 'unstructured': 'Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in ' 'adults with mild COVID-19: a randomized, double-blind, multicentre, ' 'placebo-controlled clinical trial. Clin Microbiol Infect. 2022. ' 'https://doi.org/10.1016/j.cmi.2021.12.026.', 'DOI': '10.1016/j.cmi.2021.12.026'}, { 'key': '617_CR13', 'doi-asserted-by': 'publisher', 'first-page': 'ofab563', 'DOI': '10.1093/ofid/ofab563', 'volume': '8', 'author': 'RW Finberg', 'year': '2021', 'unstructured': 'Finberg RW, Ashraf M, Julg B, et al. US201 study: a phase 2, randomized ' 'proof-of-concept trial of favipiravir for the treatment of COVID-19. ' 'Open Forum Infect Dis. 2021;8:ofab563.', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '617_CR14', 'doi-asserted-by': 'publisher', 'first-page': 'e3677', 'DOI': '10.1093/cid/ciaa1470', 'volume': '73', 'author': 'N Matsunaga', 'year': '2020', 'unstructured': 'Matsunaga N, Hayakawa K, Terada M, et al. Clinical epidemiology of ' 'hospitalized patients with COVID-19 in Japan: report of the COVID-19 ' 'Registry Japan. Clin Infect Dis. 2020;73:e3677–89.', 'journal-title': 'Clin Infect Dis'}, { 'key': '617_CR15', 'doi-asserted-by': 'publisher', 'first-page': '377', 'DOI': '10.1016/j.jbi.2008.08.010', 'volume': '42', 'author': 'PA Harris', 'year': '2009', 'unstructured': 'Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research ' 'electronic data capture (REDCap)—a metadata-driven methodology and ' 'workflow process for providing translational research informatics ' 'support. J Biomed Inform. 2009;42:377–81.', 'journal-title': 'J Biomed Inform'}, { 'key': '617_CR16', 'unstructured': 'Ministry of Health, Labour and Welfare. Clinical Guideline for COVID-19. ' 'https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00111.html. ' 'Accessed 12 Aug 2021.'}, { 'key': '617_CR17', 'doi-asserted-by': 'publisher', 'first-page': '1101', 'DOI': '10.1002/pds.5083', 'volume': '29', 'author': 'S Suissa', 'year': '2020', 'unstructured': 'Suissa S, Dell’Aniello S. Time-related biases in pharmacoepidemiology. ' 'Pharmacoepidemiol Drug Saf. 2020;29:1101–10.', 'journal-title': 'Pharmacoepidemiol Drug Saf'}, { 'key': '617_CR18', 'doi-asserted-by': 'publisher', 'first-page': '70', 'DOI': '10.1016/j.jclinepi.2016.04.014', 'volume': '79', 'author': 'MA Hernán', 'year': '2016', 'unstructured': 'Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a ' 'target trial prevents immortal time bias and other self-inflicted ' 'injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5.', 'journal-title': 'J Clin Epidemiol'}, { 'key': '617_CR19', 'doi-asserted-by': 'publisher', 'author': 'S Tsuzuki', 'year': '2021', 'unstructured': 'Tsuzuki S, Hayakawa K, Uemura Y, et al. Efficacy of remdesivir in ' 'hospitalised COVID-19 patients in Japan: a large observational study ' 'using the COVID-19 Registry Japan. medRxiv. 2021. ' 'https://doi.org/10.1101/2021.03.09.21253183v2.', 'journal-title': 'medRxiv', 'DOI': '10.1101/2021.03.09.21253183v2'}, { 'key': '617_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'k182', 'DOI': '10.1136/bmj.k182', 'volume': '360', 'author': 'MA Hernán', 'year': '2018', 'unstructured': 'Hernán MA. How to estimate the effect of treatment duration on survival ' 'outcomes using observational data. BMJ. 2018;360:k182.', 'journal-title': 'BMJ'}, { 'key': '617_CR21', 'doi-asserted-by': 'publisher', 'first-page': '779', 'DOI': '10.1111/j.0006-341X.2000.00779.x', 'volume': '56', 'author': 'JM Robins', 'year': '2000', 'unstructured': 'Robins JM, Finkelstein DM. Correcting for noncompliance and dependent ' 'censoring in an AIDS clinical trial with inverse probability of ' 'censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779–88.', 'journal-title': 'Biometrics'}, { 'key': '617_CR22', 'unstructured': 'The National Health Service England. National Early Warning Score ' '(NEWS). ' 'https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/. ' 'Accessed 28 Jan 2021.'}, { 'key': '617_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'volume': '323', 'author': 'Z Wu', 'year': '2020', 'unstructured': 'Wu Z, McGoogan JM. Characteristics of and Important lessons from the ' 'coronavirus disease 2019 (COVID-19) outbreak in China: summary of a ' 'report of 72,314 cases from the Chinese Center for Disease Control and ' 'Prevention. JAMA. 2020;323:1239.', 'journal-title': 'JAMA'}, { 'key': '617_CR24', 'doi-asserted-by': 'publisher', 'first-page': 'm1966', 'DOI': '10.1136/bmj.m1966', 'volume': '369', 'author': 'CM Petrilli', 'year': '2020', 'unstructured': 'Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital ' 'admission and critical illness among 5279 people with coronavirus ' 'disease 2019 in New York City: prospective cohort study. BMJ. ' '2020;369:m1966.', 'journal-title': 'BMJ'}, { 'key': '617_CR25', 'doi-asserted-by': 'publisher', 'first-page': '430', 'DOI': '10.1038/s41586-020-2521-4', 'volume': '584', 'author': 'EJ Williamson', 'year': '2020', 'unstructured': 'Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with ' 'COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.', 'journal-title': 'Nature'}, { 'key': '617_CR26', 'doi-asserted-by': 'publisher', 'first-page': '379', 'DOI': '10.1001/jamainternmed.2020.5313', 'volume': '181', 'author': 'JW Cunningham', 'year': '2020', 'unstructured': 'Cunningham JW, Vaduganathan M, Claggett BL, et al. Clinical outcomes in ' 'young US adults hospitalized with COVID-19. JAMA Intern Med. ' '2020;181:379–81.', 'journal-title': 'JAMA Intern Med'}, { 'key': '617_CR27', 'doi-asserted-by': 'publisher', 'first-page': '896', 'DOI': '10.1093/cid/ciaa415', 'volume': '71', 'author': 'J Lighter', 'year': '2020', 'unstructured': 'Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger ' 'than 60 years is a risk factor for COVID-19 hospital admission. Clin ' 'Infect Dis. 2020;71:896–7.', 'journal-title': 'Clin Infect Dis'}, { 'key': '617_CR28', 'doi-asserted-by': 'publisher', 'first-page': '773', 'DOI': '10.7326/M20-3742', 'volume': '173', 'author': 'SY Tartof', 'year': '2020', 'unstructured': 'Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients ' 'diagnosed with COVID-19: results from an integrated health care ' 'organization. Ann Intern Med. 2020;173:773–81.', 'journal-title': 'Ann Intern Med'}, { 'key': '617_CR29', 'unstructured': 'R Core Team. R: a language and environment for statistical computing. ' 'Vienna, Austria: R Foundation for Statistical Computing; 2018.'}, { 'key': '617_CR30', 'unstructured': 'Appili Therapeutics provides update on phase 3 PRESECO clinical trial ' 'evaluating Avigan®/Reeqonus™. Appili—LIVE. ' 'https://www.appilitherapeutics.com/newsfeed/Appili-Therapeutics-Provides-Update-on-Phase-3-PRESECO-Clinical-Trial-Evaluating-Avigan%C2%AE%2FReeqonus%E2%84%A2. ' 'Accessed 17 Nov 2021.'}, { 'key': '617_CR31', 'unstructured': 'National Institutes of Health. Information on COVID-19 treatment, ' 'prevention and research. COVID-19 treatment guidelines. ' 'https://www.covid19treatmentguidelines.nih.gov/. Accessed 27 Jan 2021.'}, { 'key': '617_CR32', 'unstructured': 'World Health Organization. Therapeutics and COVID-19: living guideline. ' 'https://www.who.int/publications-detail-redirect/therapeutics-and-covid-19-living-guideline. ' 'Accessed 27 Jan 2021.'}, { 'key': '617_CR33', 'unstructured': 'CDC. Coronavirus disease 2019 (COVID-19). Centers for Disease Control ' 'and Prevention. 2020. ' 'https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed 12 Aug ' '2021.'}, { 'key': '617_CR34', 'unstructured': 'Prime Minister’s Office of Japan. About novel coronavirus vaccine. ' 'https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html. Accessed 18 ' 'Nov 2021.'}, { 'key': '617_CR35', 'unstructured': 'Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic ' '(COVID-19). Our world in data. 2020. ' 'https://ourworldindata.org/covid-vaccinations. Accessed 18 Nov 2021.'}, { 'key': '617_CR36', 'doi-asserted-by': 'publisher', 'first-page': '85', 'DOI': '10.1016/j.antiviral.2018.03.003', 'volume': '153', 'author': 'L Delang', 'year': '2018', 'unstructured': 'Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential ' 'countermeasure against neglected and emerging RNA viruses. Antivir Res. ' '2018;153:85–94.', 'journal-title': 'Antivir Res'}, { 'key': '617_CR37', 'doi-asserted-by': 'publisher', 'first-page': '45', 'DOI': '10.1016/S2055-6640(20)30016-9', 'volume': '6', 'author': 'V Pilkington', 'year': '2020', 'unstructured': 'Pilkington V, Pepperrell T, Hill A. A review of the safety of ' 'favipiravir—a potential treatment in the COVID-19 pandemic? J Virus ' 'Erad. 2020;6:45–51.', 'journal-title': 'J Virus Erad'}, { 'key': '617_CR38', 'doi-asserted-by': 'publisher', 'first-page': '1029', 'DOI': '10.1080/14787210.2021.1866545', 'volume': '19', 'author': 'SM Hashemian', 'year': '2021', 'unstructured': 'Hashemian SM, Farhadi T, Velayati AA. A review on favipiravir: the ' 'properties, function, and usefulness to treat COVID-19. Expert Rev Anti ' 'Infect Ther. 2021;19:1029–37.', 'journal-title': 'Expert Rev Anti Infect Ther'}, { 'key': '617_CR39', 'doi-asserted-by': 'publisher', 'first-page': '41', 'DOI': '10.1093/biomet/70.1.41', 'volume': '70', 'author': 'PR Rosenbaum', 'year': '1983', 'unstructured': 'Rosenbaum PR, Rubin DB. The central role of the propensity score in ' 'observational studies for causal effects. Biometrilca. 1983;70:41–55.', 'journal-title': 'Biometrilca'}], 'container-title': ['Infectious Diseases and Therapy'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-022-00617-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-022-00617-9/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-022-00617-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T02:14:01Z', 'timestamp': 1647828841000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-022-00617-9'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 21]]}, 'references-count': 39, 'alternative-id': ['617'], 'URL': 'http://dx.doi.org/10.1007/s40121-022-00617-9', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'issn-type': [{'value': '2193-8229', 'type': 'print'}, {'value': '2193-6382', 'type': 'electronic'}], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'published': {'date-parts': [[2022, 3, 21]]}, 'assertion': [ { 'value': '24 January 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '23 February 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '21 March 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}